Lack of Association Between Oral Bisphosphonates and Osteonecrosis Using Jaw Surgery As a Surrogate Marker

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2007 Nov 14

PMID 17999023

Citations 19

Authors

M Pazianas

W A Blumentals

P D Miller

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Using jaw surgery as a surrogate marker for osteonecrosis of the jaw, this exploratory study did not find that the risk of jaw surgery was significantly increased with the use of oral bisphosphonates in postmenopausal women.

Introduction: The objective of this analysis was to explore the potential association between jaw surgery (as a surrogate marker for osteonecrosis of the jaw) and the use of oral bisphosphonates in postmenopausal women.

Methods: A claims database was used to identify female patients > or = 45 years of age with jaw surgery claims from January 1, 2002 to December 31, 2005. Four controls (patients with no claims for jaw surgery) were matched to each jaw surgery case. Additional patient data collected included oral bisphosphonate prescriptions (including alendronate, risedronate, or ibandronate) and comorbid conditions.

Results: A total of 697 jaw surgery cases and 2,808 controls were identified. Of those jaw surgery cases, 96 (13.8%) received at least one prescription for an oral bisphosphonate. After adjustment for confounding variables, receiving at least one oral bisphosphonate prescription was not shown to significantly increase the risk of jaw surgery (odds ratio(adjusted) = 0.91; 95% confidence interval = 0.70-1.19). When bisphosphonate use was stratified by duration on therapy, no significant increases in the risk of jaw surgery were observed in any group.

Conclusions: This exploratory analysis did not find a significant association between oral bisphosphonate use and increased risk of jaw surgery, a surrogate marker for osteonecrosis of the jaw.

Citing Articles

Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Khan A, Morrison A, Cheung A, Hashem W, Compston J Osteoporos Int. 2015; 27(3):853-859.

PMID: 26493811 DOI: 10.1007/s00198-015-3335-3.

Short-term and long-term effects of osteoporosis therapies.

Reid I Nat Rev Endocrinol. 2015; 11(7):418-28.

PMID: 25963272 DOI: 10.1038/nrendo.2015.71.

Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.

Lin T, Yang C, Yang Y, Lin S Osteoporos Int. 2014; 25(5):1503-11.

PMID: 24515577 DOI: 10.1007/s00198-014-2624-6.

Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis.

Lee S, Chang S, Lee M, Chan R, Lee C Osteoporos Int. 2013; 25(3):1131-9.

PMID: 24343364 DOI: 10.1007/s00198-013-2575-3.

Risk factors and indices of osteomyelitis of the jaw in osteoporosis patients: results from a hospital-based cohort study in Japan.

Yamazaki T, Yamori M, Tanaka S, Yamamoto K, Sumi E, Nishimoto-Sano M PLoS One. 2013; 8(11):e79376.

PMID: 24223935 PMC: 3815193. DOI: 10.1371/journal.pone.0079376.

References

Rogers M . New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9(32):2643-58. DOI: 10.2174/1381612033453640. View

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

Lipton A . New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther. 2005; 5(6):817-32. DOI: 10.1517/14712598.5.6.817. View

Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A . Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006; 24(6):945-52. DOI: 10.1200/JCO.2005.04.2465. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Zavras A, Zhu S . Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?. J Oral Maxillofac Surg. 2006; 64(6):917-23. DOI: 10.1016/j.joms.2006.02.011. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

Wilkinson G, Kuo Y, Freeman J, Goodwin J . Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007; 99(13):1016-24. DOI: 10.1093/jnci/djm025. View

Coxon F, Thompson K, Rogers M . Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006; 6(3):307-12. DOI: 10.1016/j.coph.2006.03.005. View

10.

. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-76. DOI: 10.1016/j.joms.2006.11.003. View

11.

Ruggiero S, Fantasia J, Carlson E . Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(4):433-41. DOI: 10.1016/j.tripleo.2006.06.004. View

12.

Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-41. DOI: 10.1016/s0140-6736(96)07088-2. View

13.

Pazianas M, Blumentals W, Miller P . Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int. 2007; 19(6):773-9. PMC: 2358932. DOI: 10.1007/s00198-007-0547-1. View

14.

Woo S, Hellstein J, Kalmar J . Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144(10):753-61. DOI: 10.7326/0003-4819-144-10-200605160-00009. View

15.

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

16.

Chesnut C, Ettinger M, Miller P, Baylink D, Emkey R, Harris S . Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin. 2005; 21(3):391-401. DOI: 10.1185/030079905X30752. View

17.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

18.

Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R . Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-99. DOI: 10.1056/NEJMoa030897. View

19.

Purcell P, Boyd I . Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005; 182(8):417-8. DOI: 10.5694/j.1326-5377.2005.tb06762.x. View

20.

Pazianas M, Miller P, Blumentals W, Bernal M, Kothawala P . A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29(8):1548-58. DOI: 10.1016/j.clinthera.2007.08.008. View